A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc.
National Institutes of Health Clinical Center (CC)
Novartis
Nurix Therapeutics, Inc.
Context Therapeutics Inc.
Checkpoint Therapeutics, Inc.
The Hospital for Sick Children
University of California, San Diego
Multitude Therapeutics Inc.
Quadriga Biosciences, Inc.
AbbVie
AbbVie
Aduro Biotech, Inc.
Abramson Cancer Center at Penn Medicine
GlaxoSmithKline
Bayer
Abramson Cancer Center at Penn Medicine
Valerio Therapeutics
Children's Oncology Group
University of Chicago
GlaxoSmithKline
National Institutes of Health Clinical Center (CC)
Astellas Pharma Inc
National Cancer Institute (NCI)
Pfizer
Anza Therapeutics, Inc.